| Generic name (Brand name) | Percentage of total spending |
|---|---|
| Perindopril/indapamide (Coversyl Plus) | 0.71% |
| Aripiprazole (Abilify) | 0.4% |
| Dabigatran (Pradaxa) | 0.12% |
| Lacosamide (Vimpat) | 0.08% |
| Alitretinoin (Toctino) | 0.06% |
| Telmisartan/amlodipine beslate (Twynsta) | 0.06% |
| Clobetasol (Clobex Spray) | 0.04% |
| Budesonide (Entocort) | 0.04% |
| Fosfomycin tromethamine (Monuro) | 0.03% |
| Lansoprazole/amoxicilline/clarithromycine (HpPAC) | 0.03% |
| Vardenafil (Levitra) | 0.02% |
| Ambrisetan (Volibris) | 0.02% |
| Dipyridamole/acetylsalicylic acid (Aggrenox) | 0.01% |
| Atovaquone (Mepron)* | 0.01% |
| Perindopril (Coversyl) | 0% |
| Lamivudine oral liquid (3-TC)* | 0% |
| Mupirocin (Bactroban Cream) | 0% |
| Triamcinolone hexacetonide injection (Aristopan) | 0% |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
April 2019
Canada
2018
Spending: Total cost of eligible prescription drugs, including the plan member’s portion as well as the plan sponsor’s portion net of any Product Listing Agreement discounts.
Traditional drugs: Medications that are easy to self-administer and require less intensive clinical monitoring, such as those used to treat diabetes and high blood pressure.
* Specialty drugs: Medications used to treat chronic, complex conditions such as severe rheumatoid arthritis, multiple sclerosis and cancer. Includes injectable and non-injectable drugs and have one or more of the following qualities: frequent dosing adjustments and intensive clinical monitoring; intensive patient training and compliance assistance; limited distribution; and/or specialized handling or administration.
